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ABSTRACT
Most patients with epithelial ovarian cancer eventually die due to recurrence. 
However, little is known about the microRNA (miRNA) expression pattern and its 
involvement in recurrent ovarian cancer. We analyzed miRNA expression profiles 
related to the recurrence of advanced ovarian high-grade serous carcinoma (HGSC) 
using miRNA microarrays. Between May 2006 and December 2012, 37 ovarian HGSC 
patients underwent secondary cyto-debulking surgery at recurrence. Among them, 
only 8 pairs of primary and recurrent tumor samples were deemed to be adequate 
for analysis. The expression profiles of primary ovarian HGSC compared with normal 
ovarian tissue were significantly consistent with those of recurrent ovarian HGSC 
compared with normal ovarian tissue (correlation coefficient = 0.81, P = 0.0078). 
Among 31 miRNAs that increased by more than 4-fold in primary tumors compared 
with normal ovarian tissue, 27 were also significantly increased in recurrent tumor 
samples. Likewise, among 35 miRNAs that decreased by more than 4-fold in primary 
tumors compared with normal ovarian tissue, 34 were also significantly decreased in 
recurrent tumor samples. We identified 60 miRNAs that were significantly increased 
in recurrent serous ovarian carcinoma compared with primary tumor tissue, including 
miR-630, miR-370, and miR-575. Additionally, 52 miRNAs were significantly decreased 
in recurrent samples, including miR-509-3p, miR-514a-3p, and miR-506-3p. Our 
results demonstrate that primary and recurrent ovarian HGSC displayed similar miRNA 
expression patterns. Nevertheless, altered miRNA expression could be implicated in 
the recurrence of ovarian HGSC, and further study is needed to validate these data 
in independent cases using a homogeneous methodology.
INTRODUCTION
Epithelial ovarian cancer is the most lethal 
malignancy among gynecological cancers, reflecting early 
peritoneal dissemination with advanced-stage disease 
at diagnosis [1]. The incidence of ovarian carcinoma 
exceeded 22,000 new cases in the United States in 
2012 and was responsible for approximately 14,000 
cancer-related deaths [2]. Although radical surgery and 
chemotherapy frequently afford complete remission, most 
patients eventually succumb to chemoresistant disease 
[1]. Therefore, a greater understanding of the molecular 
mechanisms related to recurrence is needed for the 
development of enhanced therapeutic approaches to treat 
ovarian cancer.
MicroRNAs (miRNAs) are non-coding, single-
stranded RNAs of approximately 22 nucleotides in 
length that constitute a novel class of gene regulators [3]. 
miRNAs are involved in various biological processes, 
including cell differentiation, proliferation, apoptosis, 
carcinogenesis, and metabolism [4]. Although previous 
studies have characterized gene expression profiles, 
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including those of miRNAs, in primary ovarian cancers 
[5–7], only limited data are available regarding miRNA 
gene expression profiles in recurrent ovarian cancers 
[8–13]. This is largely due to a lack of available tumor 
specimens from recurrent ovarian cancer patients, since 
secondary surgeries or biopsies are rarely performed in 
these patients. In addition, there are no suitable in vitro 
or in vivo pre-clinical models to study recurrent cancers.
In this study, we analyzed miRNA expression 
profiles associated with the recurrence of advanced high-
grade serous ovarian carcinoma (HGSC). To minimize the 
effect of genetic differences among individual patients, 
we evaluated paired primary ovarian tumor tissue and 
corresponding tumor tissue from the same patients at 
recurrence.
RESULTS
Comparison of miRNA expression profiles 
between fresh-frozen and paraffin-embedded 
ovarian cancer tissue
To determine whether miRNA expression profiles 
are preserved in FFPE specimens compared with those 
in SF specimens, expression of 1205 human miRNAs in 
SF and FFPE specimens were compared using miRNA 
microarrays. All patients had primary advanced ovarian 
HGSC (Supplementary Table S1). Five samples in SF 
tissues and five corresponding FFPE samples from the 
same patients were compared using a Pearson correlation 
test (Figure 1). Three SF normal ovarian tissue samples 
from patients treated for benign uterine disease were used 
as a control. There was a significant correlation between 
the expression of each miRNA in all samples (P < 0.001).
Patient characteristics
miRNA expression profiles associated with recurrent 
ovarian HGSC were analyzed in eight patients. All 
patients were in an advanced disease stage and primary 
cyto-debulking operations were performed in all cases 
(Table 1). All patients received post-operative adjuvant 
chemotherapy (POAC) consisting of six courses of 
paclitaxel and carboplatin. Secondary cytoreductive 
operations were performed at recurrence in seven patients. 
One patient (P3) had palliative surgery immediately 
following POAC due to intestinal obstruction; a tumor 
sample was obtained during this surgery. Two patients 
(P1 and P4) had platinum-sensitive recurrence and 
five patients (P2, P5, P6, P7, and P8) had marginally 
platinum-sensitive recurrence (platinum-free interval: 
6–12 months). The median number of chemotherapy lines 
before secondary surgery was 2, with a range of 1 to 4 
chemotherapy lines. In four patients (P1, P2, P3, and P4), 
specimens from both primary cyto-debulking operations 
and secondary surgeries were stored as SF tissue, and 
specimens from the other patients (P5, P6, P7, and P8) 
were stored as FFPE tissue.
miRNA expression profiles associated with 
recurrence in advanced HGSC
Eight pairs of primary-recurrent samples from eight 
patients were analyzed, with four normal ovarian tissue 
samples used as controls (Figure 2). miRNA expression 
profiles were compared between primary ovarian cancer 
tissue and normal ovarian tissue, recurrent ovarian cancer 
tissue and normal ovarian tissue, and recurrent ovarian 
cancer tissue and primary ovarian cancer tissue. In the 
comparison of primary ovarian HGSC with normal 
ovarian tissue, 57 miRNAs were significantly increased 
and 73 miRNAs were significantly decreased. These 
altered miRNA profiles are in agreement with previous 
findings [5]. In recurrent ovarian HGSC compared 
with normal ovarian tissue, 80 miRNAs were increased 
and 119 miRNAs were decreased. In recurrent ovarian 
HGSC compared with primary ovarian cancer tissue, 60 
miRNAs, including miR-630, miR-370, and miR-575, were 
significantly increased and 52 miRNAs, including miR-
509-3p, miR-514a-3p, and miR-506-3p, were decreased 
(Table 2). The top differentially expressed miRNAs 
(>2-fold change) in recurrent ovarian HGSC compared 
with primary HGSC are listed in Table 3. In addition, SF 
samples tended to cluster separately from FFPE samples, 
except for samples P3 and R3, in the heatmap (Figure 2).
Similar profiles of differentially expressed 
miRNAs in primary and recurrent ovarian 
HGSC compared with normal ovarian tissue
Among the 31 miRNAs that were increased by more 
than 4-fold in primary tumors, 27 were also significantly 
increased in recurrent tumor samples. Likewise, among 
the 35 miRNAs that were decreased by more than 4-fold 
in primary tumors, 34 were also significantly decreased 
in recurrent tumor samples (Figure 3, Supplementary 
Tables S2 and S3). Overall, the differentially expressed 
miRNAs identified in primary HGSC and recurrent 
HGSC compared with normal ovarian tissue were 
largely consistent. Specifically, miR-200a, b, c, miR-
141, and miR-429 were significantly increased in both 
primary and recurrent ovarian HGSC, and miR-125, miR-
99a, and miR-145 were significantly decreased in both 
primary and recurrent ovarian HGSC. The expression 
profiles of miRNAs in primary ovarian HGSC compared 
with normal ovarian tissue significantly correlated 
with those in recurrent ovarian HGSC compared with 
normal ovarian tissue (correlation coefficient = 0.81, 
P = 0.0078). In addition, primary and recurrent ovarian 
HGSC samples were not separated in three-dimensional 
principal component analysis, although the normal ovarian 
specimens clustered together.
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Figure 1: Comparison of miRNA expression between fresh snap-frozen (SF) and paraffin-embedded (FFPE) ovarian 
cancer tissue. All patients had primary advanced serous ovarian cancer. A. Five samples in SF tissues and five corresponding FFPE 
samples from the same patients were compared. B. A significant correlation was observed between the miRNA expression profiles of snap-
frozen tissue and FFPE tissue in five patients (AOC-a, b, c, d, and e). (P < 0.001).
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Table 1: Patient characteristics
Patient 
number
Tissue 
type
Stage Grade
Date of 
primary 
surgery
Number of 
chemotherapy 
lines
Date of 
secondary 
surgery
Site of 
recurrent 
tumor
PFS Recurrence 
type
P1 SF IIIc G3 2010-02-08 1 2011-12-01 Pelvic cavity 16 PS
P2 SF IIIc G2 2010-12-09 1 2011-12-16 Lymph node 8 PS
P3 SF IIIc G2 2011-11-23 1 2012-07-10 Abdominal wall 0 PR
P4 SF IIIa G3 2009-10-05 1 2012-05-16 Pelvic cavity 27 PS
P5 FFPE IIIc G3 2006-05-30 3 2009-12-02 Left psoas muscle 6 PS
P6 FFPE IV G3 2010-12-24 1 2011-12-06 Sub-hepatic mass 6 PS
P7 FFPE IV G2 2011-08-18 1 2012-08-23 Liver 7 PS
P8 FFPE IIIc G3 2010-04-01 1 2011-03-23 Pelvic cavity 8 PS
PFS, progression-free survival (between the last chemotherapy and the date of secondary surgery); SF, snap-frozen; FFPE, 
formalin-fixed, paraffin-embedded; PS, platinum-sensitive recurrence; PS, platinum-resistant recurrence.
Figure 2: MicroRNA microarray analysis. A. Eight pairs of primary-recurrent samples from eight patients were analyzed, and four 
normal ovarian tissue samples were used as a control. B. Significantly altered miRNAs are shown on a heatmap.
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Validation of miRNA results
Among the differentially expressed miRNAs, 
5–6 were subjected to qRT-PCR analysis to validate the 
miRNA microarray results. We selected miR-141, miR-
200c, miR-205, miR-429, miR-204, miR-506, and miR-
509-3p, which were differentially expressed between 
normal ovarian tissue and ovarian HGSC (Figure 4). In 
agreement with the microarray results, the expression 
levels of miR-141, miR-200c, miR-205, and miR-429 were 
increased, whereas those of miR-204, miR-506, and miR-
509-3p were decreased in HGSC. We selected miR-630, 
miR-370, miR-575, miR-506, and miR-509-3p, which were 
differentially expressed between recurrent and primary 
ovarian HGSC. For the selected miRNAs, the P-value 
and FDR were calculated and were found to be significant 
(<0.05, Supplementary Table S4). In agreement with the 
microarray results, the expression levels of miR-630, 
miR-370, and miR-575 were increased, whereas those of 
miR-506 and miR-509-3p were decreased in the recurrent 
samples. Thus, the microarray data were validated, 
warranting further miRNA analyses in a clinical setting.
DISCUSSION
In this study, we determined that the miRNA 
expression profiles in primary and recurrent ovarian 
HGSC were consistent (correlation coefficient = 0.81, P 
= 0.0078). Although some miRNAs were significantly 
increased or decreased in recurrent ovarian HGSC, most 
of the miRNAs matched with those of primary HGSC 
samples. To our knowledge, this is the first study to show a 
similarity of miRNA expression profiles between primary 
and recurrent ovarian HGSC.
A few previous studies explored miRNA expression 
profiles in recurrent ovarian HGSC compared with 
primary HGSC [10–13]. Laios et al. reported that miR-
9 and miR-223 are potential biomarkers of recurrent 
epithelial ovarian cancer [11]. Chong et al. compared 
miRNA expression profiles in primary and recurrent 
ovarian serous carcinoma tissue [12]. However, primary 
and recurrent tumor specimens were not taken from the 
same patient in that study. Therefore, their resulting list of 
differentially expressed miRNAs was not consistent with 
our present data.
Table 2: Numbers of significantly increased and decreased miRNAs identified using miRNA microarrays
 Significantly increased miRNAs Significantly decreased miRNAs
Primary ovarian HGSC vs. normal 
ovarian tissue 57 73
Recurrent ovarian HGSC vs. normal 
ovarian tissue 80 119
Recurrent ovarian HGSC vs. primary 
ovarian HGSC 60 52
HGSC, high-grade serous carcinoma.
Table 3: Top differentially expressed miRNAs with >2-fold change in recurrent ovarian HGSC compared with 
primary ovarian tumor HGSC
Increased miRNAs Fold change
(log2 scale)
Decreased miRNAs Fold change
(log2 scale)
hsa-miR-630 2.48039 hsa-miR-509-3p -3.6413
hsa-miR-370 2.09488 hsa-miR-514a-3p -3.127
hsa-miR-575 2.08748 hsa-miR-506-3p -2.4918
hsa-miR-3692-5p 1.72906 hsa-miR-508-3p -2.3845
hsa-miR-4270 1.67729 hsa-miR-509-3-5p -2.3436
hsa-miR-548q 1.67019 hsa-miR-95 -2.3274
hsa-miR-135a-3p 1.63426 hsa-miR-30a-3p -2.2598
hsa-miR-1207-5p 1.62239 hsa-miR-362-5p -2.0035
hsa-miR-4281 1.60895 hsa-miR-30b-5p -2.0014
hsa-miR-671-5p 1.59902 hsa-miR-30e-3p -1.9538
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Figure 3: Characterization of miRNA expression. A. Among 31 microRNAs upregulated by more than 4-fold in primary tumors, 
27 were also significantly upregulated in recurrent tumor samples. B. Likewise, among 35 microRNAs downregulated by more than 4-fold 
in primary tumors, 34 were also significantly downregulated in recurrent tumor samples. C. Expression profiles of miRNAs in primary 
ovarian HGSC compared with those of normal ovarian tissue were similar to those in recurrent ovarian HGSC compared with normal 
ovarian tissue (correlation coefficient = 0.811, P = 0.0078). D. Primary and recurrent ovarian HGSC samples were not separated in three-
dimensional principal components analysis, although normal ovarian specimens clustered together.
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Figure 4: Real-time RT-PCR verification of the miRNA microarray results. A. Differentially expressed miRNAs in primary 
ovarian HGSC (n = 8) compared with normal ovarian tissue (n = 4) from miRNA microarray experiments were consistent with data 
obtained using qRT-PCR. B. Differentially expressed miRNAs in recurrent ovarian HGSC (n = 8) compared with normal ovarian tissue (n 
= 4). C. Differentially expressed miRNAs in recurrent ovarian HGSC (n = 8) compared with primary HGSC (n = 8). Results are the mean 
± standard deviation of three independent experiments performed in triplicate. (*P < 0.05).
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Recently, a whole-genome characterization of 
chemoresistant ovarian cancer tissue was published [13]. 
The authors showed that relapse samples had a higher 
mutational burden (single nucleotide variants and indels) 
at both the coding and non-coding levels than matched 
primary samples, suggesting that HGSC continues to 
evolve during treatment. In concordance with these 
findings, we found that recurrent tumors had a higher 
number of significantly increased or decreased miRNAs 
(Table 2).
The reason for the miRNA expression similarity 
between primary and recurrent HGSC has not yet been 
elucidated. We speculate that miRNAs are highly 
conserved throughout the species [14], and that miRNA 
profiles are not largely changed under the selective 
pressure of chemotherapy. Otherwise, HGSC may undergo 
clonal evolution under treatment, such that miRNA 
expression profiles of primary tumors could be conserved 
at recurrence.
Nevertheless, some miRNAs were significantly 
increased or decreased in recurrent HGSC compared with 
primary HGSC. The most significantly increased miRNA 
in recurrent HGSC observed was miR-630. Increased 
expression of miR-630 in gastric cancer and colorectal 
cancer has been reported to be associated with poor 
survival [15, 16]. A proposed mechanism is that miR-630 
inhibits p53 activation by limiting the early DNA damage 
response [17]. miR-630 was found to be increased in non-
small cell lung cancer cells and head and neck squamous 
cell carcinoma cells in response to cisplatin treatment [18]. 
Upregulation of miR-630 was also observed in epithelial 
ovarian cancer, and downregulation of miR-630 using an 
inhibitor improved the chemosensitivity of ovarian cancer 
cells to cisplatin [19]. Thus, further functional validation 
of miR-630 should be performed.
In the present study, we used different tissue types 
(SF and FFPE) for miRNA expression analyses. Previous 
miRNA expression studies have typically used FFPE 
specimens, and have shown that the miRNAs remain 
largely intact in routinely processed FFPE clinical 
specimens [20–22]. In agreement with previous studies, 
we also demonstrated strong correlations between 
expression profiles in matched SF and FFPE specimens. In 
addition, miRNA expression profiles obtained using SF + 
FFPE specimens in primary ovarian HGSC compared with 
normal ovarian tissue were consistent with previous results 
obtained using SF specimens used for miRNA analysis 
of primary ovarian HGSC [5]. However, the SF samples 
tended to cluster separately from FFPE samples, except 
for P3 and R3, in the heatmap (Figure 3). These findings 
indicate that pooling different tissue types together could 
affect the miRNA expression profiling results.
A limitation of our study is that we did not perform 
correlation analyses between miRNA expression profiles 
and clinicopathologic factors owing to the limited number 
of cases. With the exception of one patient, the patients 
included in this study had chemosensitive recurrence at 
secondary surgery. Secondary cyto-debulking operations 
are usually considered in only platinum-sensitive recurrent 
cases. In addition, recurrent HGSC specimens usually 
have extensive fibrosis. Although we used samples with a 
high tumor percentage, the presence of fibrosis may have 
led to confounding miRNA expression results.
In conclusion, primary and recurrent ovarian 
HGSC displayed similar miRNA expression patterns. 
Nevertheless, some altered miRNAs could be implicated 
in the recurrence of ovarian HGSC, and therefore further 
studies are required to determine the functional role of 
differentially expressed miRNAs in recurrent ovarian 
HGSC.
MATERIALS AND METHODS
Patients and study design
The experimental protocol was approved by the 
Institutional Review Board of the Yonsei University 
College of Medicine (4-2012-0741). Between May 
2006 and December 2012, 37 ovarian HGSC patients 
underwent secondary debulking surgery at recurrence 
(Figure 5). Among them, 15 patients received neo-
adjuvant chemotherapy before primary surgery was 
excluded. Nine patients that underwent primary surgery at 
another institution were excluded because primary tumor 
tissues were not available. Finally, three patients were 
excluded because of the low quality of samples, and one 
patient was excluded owing to failure of deparaffinization. 
Therefore, for the final analysis, eight pairs of primary-
recurrent tumor tissues from eight patients were used 
for miRNA microarray analysis. Snap-frozen fresh (SF) 
tissues stored in liquid nitrogen and archival formalin-
fixed, paraffin-embedded (FFPE) tissues were used for 
miRNA expression analyses. This strategy was used 
because ovarian tumor samples with both primary and 
corresponding recurrent samples preserved as SF tissues 
were limited. Therefore, we initially validated the miRNA 
expression profiles of FFPE-preserved tissues compared 
with those of SF-preserved tissues. Four SF normal 
ovarian tissue samples from patients treated for benign 
uterine disease were used as a control; the age of the 
control patients ranged from 49 to 60 years. For primary 
HGSC, FFPE tissues were sampled at the point where the 
tumor percentage was above 90% based on hematoxylin 
and eosin (H&E) staining, and 10-μm serial sectioning 
was performed. In recurrent HGSC, the tumor density is 
relatively low and tumors are surrounded by stromal cells. 
Therefore, core tissue (2 mm) was obtained using a hollow 
needle at the point where the tumor percentage was above 
90% based on H&E staining, as performed for the tissue 
microarrays.
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RNA preparation
Frozen tissue samples were homogenized in 
TRIzol® reagent (Invitrogen, Glasgow, UK) using 
an Omni-Mixer Homogenizer (Omni International, 
Kennesaw, GA, USA). Total RNA was then isolated 
according to the manufacturer’s instructions. FFPE 
specimens were deparaffinized in xylene (tissue slides, 
3 min; tissue core, overnight), and total RNA isolation 
was performed using a QIAamp RNA Mini Kit (Qiagen, 
Hilden, Germany). RNA quantity was assessed using 
a Nanodrop 1000A spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA), and RNA quality 
was assessed using an Agilent 2100 Bioanalyzer and RNA 
6000 Nano Chip (Agilent Technologies, Amstelveen, the 
Netherlands).
miRNA microarray analysis
Samples of total RNA (100 ng) containing miRNA 
were labeled with cyanine 3-pGp (Cy3) using an Agilent 
miRNA Complete Labeling and Hyb Kit (Agilent 
Technologies, Santa Clara, CA, USA). Samples were 
placed on an Agilent Human miRNA v14 chip (AMDID 
029297) and covered with a Gasket slide (Agilent 
Technologies, Santa Clara, CA, USA). Slides were 
hybridized for 16 h at 42°C using an Agilent hybridization 
system. miRNA arrays were analyzed using GeneSpring 
GX v11.5 (Agilent Technologies, Santa Clara, CA, USA) 
with standard normalization methods for one-channel 
microarrays with percentile median normalization 
methods. Fold-change values were calculated for unpaired 
comparisons between normal and test samples, and then 
averaged to generate a mean fold-change value. Welch's 
t-tests were used to determine statistical significance. 
Target predictions of significantly modified miRNAs 
were analyzed using the TargetScan 5.1 and miRBase v16 
databases. miRNA microarray data from this study have 
been submitted to the Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/info/geo_agil.html) 
under accession number GSE83693.
Reverse transcription and quantitative real-time 
reverse transcription-polymerase chain reaction 
(qRT-PCR)
To validate results of the miRNA microarray 
experiments, the five most differentially expressed 
miRNAs were further evaluated using qRT-PCR. Total 
miRNA was isolated using a mirVANA microRNA 
Isolation Kit (Ambion, Austin, TX, USA) according to 
the manufacturer’s protocol. Synthesis of cDNA was 
Figure 5: Study design and patient selection.
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performed using TaqMan MicroRNA Assays (Applied 
Biosystems, Foster City, CA, USA). qRT-PCR was 
performed using an Applied Biosystems Prism 7500 
Fast Sequence Detection System (Applied Biosystems, 
Warrington, UK) according to the manufacturer’s 
protocol. Relative gene expression was analyzed using the 
2-ΔΔCT method, and results are expressed as the fold-change 
relative to control values. All experiments were repeated 
three times.
Statistical analysis
To ensure the accuracy of microarray data analysis, 
false discovery rate (FDR)-adjusted P-values (q-values) 
were calculated using the methods reported by Storey [23]. 
The qRT-PCR data are expressed as the mean ± standard 
deviation of at least three independent experiments. 
Significance was determined using the Student’s t-test. 
Comparison of miRNA expression profiles was performed 
using Pearson correlation. Statistical analyses were 
performed using SPSS (Version 18.0, SPSS, Inc., USA).
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